KRAS 저해제 : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• KRAS is the most frequently mutated of the three RAS genes, followed by NRAS and HRAS. KRAS mutations are commonly associated with several types of cancer, including pancreatic, colorectal, lung adenocarcinomas, ovarian, and others.
• Among the 7MM, the United States captured the highest KRAS-inhibitors market size in 2025, accounting for nearly 70% of the total market share.
• Among the approved therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenue generated during the study period (2022-2036).
• The United States had the highest number of KRAS mutation cases in NSCLC among the 7MM. Approximately 46% of all KRAS mutation cases in NSCLC in the 7MM were reported in the United States.
• The G12D variant is especially found in pancreatic and ovarian cancers, which are often hard to treat, while the G12C mutation is more common in NSCLC.
• Many KRAS subtypes have no treatment options; in these casepan-KRAS-targetinging medicines can be helpful. A wider patient base will be available for such therapies. One drug that has demonstrated a pan-KRAS inhibitory impact in CRC is onvansertib. A few other companies, including ELICIO and Revolution Medicines, are researching pan-KRAS therapies.
• Many companies are focusing on developing their candidates in pan-KRAS, like Cardiff Oncology (onvansertib), Immuneering Corporation (IMM-1-104), Jacobio Pharma (JAB-23E73), Eli Lilly and Company (LY4066434), and others are expected to have tremendous market potential due to the broad target patient population they can address.
• The current landscape of KRAS-targeted drug development is heavily focused on the G12C mutation, with the majority of approved therapies and investigational agents specifically designed for this variant.
• Revolution's unique selling proposition lies in its focus on targeting the active, or "on," states of KRAS proteins. According to the company, it is the persistent "on" signaling of RAS that drives uncontrolled cellular proliferation. As such, Revolution believes its approach may offer a therapeutic advantage over KRAS "off" inhibitors such as LUMAKRAS and KRAZATI.
• Several pharmaceutical companies have recently entered the race to develop therapies targeting the KRAS G12D mutation. A few players are Tyligand Pharmaceuticals (Suzhou), Verastem Oncology and GenFleet Therapeutics, AstraZeneca, PAQ Therapeutics, Astellas Pharma, and others with additional companies rapidly emerging as interest in this high-potential target continues to grow.
• Leading Pharma companies developing therapies targeting KRAS include Roche/Chugai/Genentech (Divarasib), Revolution Medicines (Daraxonrasib), Eli Lilly and Company (Olomorasib), Merck, Taiho, and Astex Pharmaceuticals (MK-1084), Cardiff Oncology (Onvansertib), Genfleet Therapeutics and Innovent (DUPERT), Elicio Therapeutics (ELI-002), D3 Bio (D3S-001), and others with their candidates in different stages of clinical development.

DelveInsight's "Kirsten Rat Sarcoma Virus (KRAS) Inhibitors - Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the KRAS inhibitors, historical and forecasted epidemiology as well as the KRAS inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

KRAS inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted the 7MM KRAS inhibitors market size from 2022 to 2036. The report also covers current KRAS inhibitor treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2022-2036

KRAS Inhibitors Disease Understanding and Treatment Algorithm

KRAS Inhibitors Overview

KRAS belongs to a group of small GTP-binding proteins known as the RAS superfamily or RAS-like GTPases. Rat sarcoma virus (RAS), an oncogene, functions as a signal transducer, important for regulating cell proliferation, differentiation, and survival in normal and malignant cells. The RAS-mitogen-activated protein kinase-ERK kinase-extracellular signal-related kinase (RAS-RAF-MEK-ERK) pathway is one of the best-characterized signal transduction pathways, and its aberrancies are commonly implicated in the development of multiple different cancer types. KRAS mutations are genetic alterations in the KRAS gene, which encodes a protein in cell signaling pathways. These mutations are commonly found in various types of cancer, including CRC, lung, and pancreatic cancer. Unfortunately, KRAS mutations have historically been challenging to target with specific treatments. However, recent advancements in research have led to the development of some promising strategies to treat KRAS-mutated cancers, but these treatments are limited to NSCLC only.

Generally, treatment for KRAS-mutated cancers includes surgery, radiation therapy, chemotherapy, targeted therapies, immunotherapy, and others. Radiofrequency Ablation (RFA) might be considered for some people with small lung tumors near the outer edge of the lungs, especially if they cannot tolerate surgery.

KRAS Inhibitors Diagnosis

KRAS mutation can be diagnosed by conducting genetic sequencing of the tumor tissue or with the help of a liquid biopsy.

The clinician typically initiates KRAS testing requests for a patient. Usually, the testing is performed on tumor tissue removed from the patient during a previous surgery or biopsy procedure. Typically, patients undergoing KRAS testing with high-stage tumors require adjuvant therapy. If metastatic disease is present, it is important to clarify that the sample needed for testing is not the primary tumor but a representative tissue sample from the metastatic lesion. DNA is usually extracted from FFPE tissue blocks. It is the pathologist's responsibility to identify the best tumor section to be subjected to testing. This includes evaluation of the slide with cut tissue or the tissue block, followed by microdissection and macro dissection for tumor enrichment to eliminate portions of necrotic tumor and nonneoplastic tissue. Typically, tumor-enriched areas will have relatively easily identified histology and can be dissected away from benign tissue. This process is often aided by having the fixed tissue cut placed on an unstained slide and having a standard H&E-stained (hematoxylin and eosin) slide of the same tissue cut available for comparison.

KRAS Inhibitors Epidemiology

As the market is derived using a patient-based model, the KRAS inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of NSCLC, CRC, pancreatic cancer, and LGSOC, total KRAS incident cases in NSCLC, CRC, pancreatic cancer, and LGSOC, total KRAS variant cases in NSCLC, CRC, pancreatic cancer, and LGSOC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

• According to DelveInsight's analysis, the total incident cases of NSCLC were approximately 539,400 in the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan in 2025.
• Among the 7MM, the US accounted for the highest number of total incident cases of NSCLC with ~203,000 cases in 2025.
• The total incident cases of colorectal cancer were ~570,800 in the 7MM in 2025.
• Germany had the largest patient share within EU4 and the UK, accounting for ~26% of KRAS mutation cases. Whereas, Spain had the smallest patient share, i.e., ~14%.
• KRAS mutations are seen most frequently in Colorectal Cancer, and LGSOC capturing the lowest patient share. The most frequent KRAS variant observed in NSCLC is G12C. In the US, KRASG12C is present in ~36.8% of NSCLC cases. The highest rates of KRASG12D, i.e., ~41.8% and ~41.7%, were found in pancreatic cancer and LGSOC, respectively.

KRAS Inhibitors Drug Chapters

The drug chapter segment of the KRAS inhibitors reports encloses a detailed analysis of KRAS inhibitors marketed drugs such as LUMAKRAS/LUMYKRAS, KRAZATI, AVMAPKI + FAKZYNJA Co-Pack, and late-stage (Phase III and Phase II) pipeline drugs including divarasib, daraxonrasib, olomorasib, MK-1084, and others. It also helps understand the KRAS inhibitors' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included the drug, and the latest news and press releases.

Marketed Drugs

LUMAKRAS/LUMYKRAS (sotorasib): Amgen

LUMAKRAS is an inhibitor of the RAS GTPase family indicated for treating adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. It has also recieved BTD by the US FDA. The drug received accelerated approval from the FDA in May 2021 for treating patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, following at least one prior systemic therapy. Conditional marketing authorization was subsequently granted in the European Union. In January 2022, it was approved in Japan for KRAS G12C-mutated advanced or recurrent NSCLC after prior systemic therapy.

• In December 2024, Amgen stated in its Q4 presentation that LUMAKRAS has multiple patents in the US and Europe, ensuring market exclusivity until 2040.
• In December 2023, Amgen announced that the FDA issued a complete response letter for its supplemental new drug application for full approval of LUMAKRAS, based on the CodeBreaK 200 trial. The FDA also set a new postmarketing requirement for a confirmatory study to be completed by February 2028.

KRAZATI (adagrasib): Bristol Myers Squibb (Mirati Therapeutics)

KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. KRAZATI received approval from the FDA and launched commercially in the US in December 2022. In January 2024, the EC granted conditional marketing authorization for KRAZATI for treating KRASG12C-mutated advanced NSCLC and disease progression after at least one prior systemic therapy.

• In April 2025, Bristol Myers Squibb announced anticipation of Phase III trial data readouts for KRYSTAL-10 by 2026 for 2L CRC, KRYSTAL-7 trial results in 2028 for 1L NSCLC PD-L1=50%, and KRYSTAL-4 trial results in 2029 for 1L NSCLC.
• According to the company's SEC filing, the confirmatory results from the KRYSTAL-12 trial in patients with 2L+ mutated NSCLC are expected in 2025 or 2026.
• According to Q1 2025 company's presentations, KRAZATI (KRYSTAL-17) early-stage data for 1L NSCLC (TPS <50%) are expected in 2025.

Emerging Drugs

Olomorasib (LY3537982): Eli Lily and Company

Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. Olomorasib is currently being studied in 1L KRAS G12C+ NSCLC clinical trial among two other Phase III trials in NSCLC. The FDA granted BTD for olomorasib for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers and ODD for the treatment of KRAS G12C-mutant NSCLC in June 2025.

In September 2025, Eli Lilly announced that the US FDA has granted BTD to olomorasib in combination with pembrolizumab for the first-line treatment of patients with unresectable advanced or metastatic NSCLC with a KRAS G12C mutation and PD-L1 expression >= 50%, as determined by FDA approved tests.

Calderasib (MK-1084): Merck

Calderasib is an investigational oral selective KRAS G12C inhibitor being evaluated with or without pembrolizumab for the treatment of certain patients with colorectal cancer and NSCLC. MK-1084 is being developed under a collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals. Currently MK-1084 is being evaluated in Phase III KANDLELIT-012 and Phase III KANDLELIT-004 trial. Calderasib was granted BTD by the US FDA for the first-line treatment of patients with advanced or metastatic NSCLC with KRAS G12C-mutation and expressing PD-L1 in May 2026.

In March 2026, Merck announced new data from the Phase I KANDLELIT-001 trial. Findings demonstrated that calderasib both as monotherapy and in combination with pembrolizumab, provides durable antitumor activity and impressive survival rates. The ORR reached 72% in combination group and patients receiving the doublet therapy achieved a median PFS 95%.

Daraxonrasib: Revoltuion Medicines

Daraxonrasib is an investigational, oral, RAS(ON) multi-selective non-covalent inhibitor designed to treat patients with cancers driven by a wide range of common RAS mutations. The company in its SEC filling, anticipate to provide an update on advancing daraxonrasib combination therapy in 1L NSCLC in 2026. It received ODD from the US FDA for the treatment of pancreatic cancer.

In June 2025, Revoltuion Medicines entered into a clinical collaboration with Summit Therapeutics, to evaluate the safety and efficacy of daraxonrasib in combination with Summit's ivonescimab in multiple solid tumor.

Recent Developments in the KRAS Inhibitors Market

• In June 2026, Cardiff Oncology announced positive results from CRDF-004, Phase II clinical trial evaluating onvansertib in combination with SoC regimens in patients with first-line RAS-mutated mcolorectal cancer. Results showed that onvansertib demonstrated deep and durable tumor shrinkage, including clinically meaningful improvements in ORR and PFS.
• In May 2026, Silexion Therapeutics announced positive preclinical findings from an ongoing translational immuno-oncology study evaluating SIL204, in human KRAS-mutated pancreatic cancer cells. Findings showed statistically significant increase in surface expression of major histocompatibility complex class I (MHC-I), also known as HLA-ABC.
• In April 2026, Revolution Medicines announced positive topline results from its Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic PDAC who had been previously treated. It demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard of care cytotoxic chemotherapy delivered intravenously.
• In January 2026, Merck announced the initiation of KANDLELIT-007, a Phase III clinical trial evaluating calderasib + pembrolizumab and berahyaluronidase for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic non squamous NSCLC.

KRAS Inhibitors Market Outlook

KRAS is a well-established oncogene frequently mutated in several cancers, including NSCLC, PDAC, CRC, and ovarian cancer. Historically considered undruggable, KRAS has become a renewed focus with the emergence of mutation-specific inhibitors-most notably those targeting the KRAS G12C mutation. These agents, such as LUMAKRAS/LUMYKRAS (sotorasib) and KRAZATI (adagrasib), selectively inhibit KRAS in its inactive GDP-bound state, offering clinical benefit in previously treated patients with KRAS G12C-mutated tumors.

Amgen's LUMAKRAS was the first KRAS G12C inhibitor to receive FDA approval in 2021 for NSCLC, followed by approvals in multiple global markets. Subsequent approvals were extended to CRC in combination with VECTIBIX, based on data showing improved progression-free outcomes. Companion diagnostics, like Qiagen's therascreen KRAS RGQ PCR Kit, are aiding patient selection.

Bristol Myers Squibb's KRAZATI entered the market in 2022 and has since surpassed LUMAKRAS in clinical momentum, receiving accelerated approvals for use in both NSCLC and mCRC. LUMAKRAS witnessed a decrease in sales, coinciding with the launch of KRAZATI. Amgen stated that the decline in sales was primarily due to a price adjustment implemented as part of a reimbursement agreement in Germany. It has also been incorporated into NCCN Guidelines for CNS-metastatic NSCLC, solidifying its role in the evolving standard of care. Despite these advances, primary and acquired resistance to KRAS G12C inhibitors remains a key hurdle.

Beyond G12C, the need for effective therapies targeting other KRAS variants is driving next-generation drug development. Verastem's AVMAPKI FAKZYNJA Co-Pack recently became the first FDA-approved therapy for KRAS-mutated recurrent LGSOC, addressing an underserved indication. Meanwhile, combination strategies-pairing KRAS inhibitors with chemotherapy, immune checkpoint inhibitors, or pan-KRAS agents-are under active investigation.

Numerous key players actively explore alternative KRAS variants and expand their research to include other types of cancers beyond NSCLC. This shift in focus holds promising potential for developing effective therapies that can address a wider range of KRAS mutations and target multiple cancer types. Many companies are focusing on developing their candidates in pan-KRAS, like Cardiff Oncology (onvansertib), Immuneering Corporation (IMM-1-104), Verastem (Avutometinib + Defactinib), and others.

Several companies, including Roche, Revolution Medicines, Eli Lilly, and others, are advancing promising candidates such as divarasib, daraxonrasib, and olomorasib, aiming to expand the therapeutic scope of KRAS-targeted treatment across mutation subtypes and tumor types. Despite progress, KRAS-driven cancers remain challenging due to tumor heterogeneity and resistance mechanisms. Ongoing innovation in targeted therapies, biomarker-driven approaches, and combination regimens will be essentito realize the potential of KRAS inhibition in oncology fullyogy.

• Currently, there are only three KRAS based approved drugs including sotorasib, which was approved by the US FDA in May 2021 for NSCLC, adagrasib by the US FDA in December 2022 for NSCLC, and avutometinib and defactinib co-pack by US FDA in May 2025 for LGSOC.
• Among the selected indications, KRAS in NSCLC accounted for the largest market size, with nearly USD 11,100 million in the US in 2025.
• According to the estimates, the largest market size for KRAS inhibitors in NSCLC was in the US, accounting for ~70% of the 7MM market in 2025, and is anticipated to grow significantly by 2036.
• Among EU4 and the UK, avutometinib and defactinib co-pack will account for the largest market size, while Glecirasib is anticipated to stand at the bottom of the ladder in 2036.
• Amgen's 2025 annual report indicated that US sales of sotorasib (LUMAKRAS) reached approximately USD 211 million in 2025.

KRAS Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2022-2036. Further detailed analysis of emerging therapies and drug uptake is in the report.

KRAS Inhibitors Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for KRAS inhibitors emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on KRAS inhibitors evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as VCS Research Institute, Florida Cancer Specialists & Research Institute in the US, Japanese Foundation for Cancer Research in Japan, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or KRAS inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform qualitative and market intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of KRAS inhibitors, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the KRAS inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding the trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM KRAS inhibitors market.

KRAS Inhibitors Report Insights

• KRAS-targeted patient pool
• Therapeutic approaches
• KRAS inhibitors pipeline analysis
• KRAS inhibitors market size and trends
• Existing and future market opportunity

KRAS Inhibitors Report Key Strengths

• 11 years forecast
• The 7MM coverage
• KRAS inhibitors epidemiology segmentation
• Key cross competition
• Drugs uptake and key market forecast assumptions

KRAS Inhibitors Report Assessment

• Current treatment practices
• Unmet needs
• Pipeline product profiles
• Market attractiveness
• Qualitative analysis (SWOT and analyst views)

FAQs:

Market Insights

• What was the KRAS mutated cancers total market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like in 2036? What are the contributing factors for this growth?
• How will KRAZATI affect the treatment paradigm in NSCLC?
• What will be the market share of NSCLC, CRC, and pancreatic cancer in 2036?
• Which drug is going to be the largest contributor in 2036?
• What are the pricing variations among different geographies for approved therapies?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of KRAS inhibitors? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to KRAS inhibitors?
• What is the historical and forecasted KRAS inhibitors patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which type of KRAS mutation is the largest contributor in patients affected with NSCLC, CRC, and pancreatic cancer?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period?
• What are the key findings pertaining to the KRAS mutant cancer epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• Which are the approved KRAS inhibitors? What are the current treatment guidelines for treating KRAS-mutated cancers in the US and Europe?
• How many companies are developing therapies for the treatment of KRAS-mutated cancers?
• How many emerging therapies are in the mid-stage and late stage of development for treating KRAS-mutated cancers?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What key designations have been granted for the emerging therapies for KRAS inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the KRAS inhibitors market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of KRAS-mutated cancers during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand key opinion leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. KRAS Inhibitor Market Overview at a Glance

• 6.1. Market Share (%) Distribution by Therapies in 2025 in the 7MM
• 6.2. Market Share (%) Distribution by Therapies in 2036 in the 7MM
• 6.3. Market Share (%) Distribution by Indications in 2025 in the 7MM
• 6.4. Market Share (%) Distribution by Indications in 2036 in the 7MM

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Clinical Significance
  • 7.2.1. RAS Oncogene and Carcinogenesis as a Multistep Process
  • 7.2.2. KRAS Mutation as a Prognostic Biomarker
  • 7.2.3. KRAS Mutation and Personalized Medicine
• 7.3. Diagnosis
  • 7.3.1. Biomarker testing for KRAS mutation
    • 7.3.1.1. NSCLC
    • 7.3.1.2. Colorectal Cancer
    • 7.3.1.3. Pancreatic Cancer
  • 7.3.2. Clinical Relevance of KRAS Mutation by Cancer Type
    • 7.3.2.1. Pancreatic Cancer
    • 7.3.2.2. Colorectal Cancer
    • 7.3.2.3. Tumor-based Tests for KRAS Gene Mutations
    • 7.3.2.4. Lung Cancer
    • 7.3.2.5. Ovarian Cancer
    • 7.3.2.6. Hepatocellular Carcinoma (HCC)
• 7.4. Diagnostic Guidelines and Recommendations for KRAS Inhibitors
  • 7.4.1. ESMO Guidelines for Metastatic Colorectal Cancer [2025]
  • 7.4.2. NCCN Guidelines for KRAS, NRAS, and BRAF Mutation Testing in Metastatic Colorectal Cancer [2025]
  • 7.4.3. NCCN Guideline for Biomarker Testing in NSCLC [2025]
  • 7.4.4. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for CRC Treatment

8. Treatment

• 8.1. Treatment of NSCLC
  • 8.1.1. Surgery
  • 8.1.2. Radiofrequency Ablation (RFA)
  • 8.1.3. Radiation Therapy
  • 8.1.4. Chemotherapy
  • 8.1.5. Immunotherapy
• 8.2. Treatment of Pancreatic Cancer
  • 8.2.1. Surgery
  • 8.2.2. Ablation or Embolization Treatments
  • 8.2.3. Radiation Therapy
  • 8.2.4. Chemotherapy
  • 8.2.5. Immunotherapy
• 8.3. Treatment of Hepatocellular Cancer
  • 8.3.1. Surgery
  • 8.3.2. Ablation
  • 8.3.3. Embolization Therapy
  • 8.3.4. Radiation Therapy
  • 8.3.5. Targeted Drug Therapy
  • 8.3.6. Immunotherapy
  • 8.3.7. Chemotherapy
• 8.4. Treatment of Ovarian Cancer
  • 8.4.1. Local Treatments
    • 8.4.1.1. Surgery
    • 8.4.1.2. Radiation Therapy
  • 8.4.2. Systemic Treatment
    • 8.4.2.1. Chemotherapy
    • 8.4.2.2. Targeted Therapy
    • 8.4.2.3. Hormone Therapy
• 8.5. Treatment for Colorectal Cancer
  • 8.5.1. Local Treatments
    • 8.5.1.1. Surgery
    • 8.5.1.2. Radiation Therapy
  • 8.5.2. Systemic Therapy
    • 8.5.2.1. Chemotherapy
    • 8.5.2.2. Targeted Therapy
    • 8.5.2.3. Immunotherapy
• 8.6. Treatment Guidelines and Recommendations for KRAS Inhibitors
  • 8.6.1. NCCN Guidelines for the Treatment of CRC
  • 8.6.2. NCCN Guidelines for NSCLC
  • 8.6.3. ESMO Guidelines for the Treatment of Metastatic Colorectal Cancer
    • 8.6.3.1. First-line Therapy Guidelines
    • 8.6.3.2. Second-line Therapy Guidelines
    • 8.6.3.3. Third-line Therapy and Beyond Guidelines
  • 8.6.4. Pan-asian Guidelines for the Management of NSCLC

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. KRAS Mutation in NSCLC
  • 9.3.1. United States
    • 9.3.1.1. Total Incident Cases of NSCLC in the United States
    • 9.3.1.2. KRAS Incident Cases in NSCLC in the United States
    • 9.3.1.3. KRAS Variant Cases in NSCLC in the United States
  • 9.3.2. EU4 and the UK
    • 9.3.2.1. Total Incident Cases of NSCLC in EU4 and the UK
    • 9.3.2.2. KRAS Incident Cases in NSCLC in EU4 and the UK
    • 9.3.2.3. KRAS Variant Cases in NSCLC in EU4 and the UK
  • 9.3.3. Japan
    • 9.3.3.1. Total Incident Cases of NSCLC in Japan
    • 9.3.3.2. KRAS Incident Cases in NSCLC in Japan
    • 9.3.3.3. KRAS Variant Cases in NSCLC in Japan
• 9.4. KRAS Mutation in CRC
  • 9.4.1. United States
    • 9.4.1.1. Total Incident Cases of CRC in the United States
    • 9.4.1.2. KRAS Incident Cases in CRC in the United States
    • 9.4.1.3. KRAS Variant Cases in CRC in the United States
  • 9.4.2. EU4 and the UK
    • 9.4.2.1. Total Incident Cases of CRC in EU4 and the UK
    • 9.4.2.2. KRAS Incident Cases in CRC in EU4 and the UK
    • 9.4.2.3. KRAS Variant Cases in CRC in EU4 and the UK
  • 9.4.3. Japan
    • 9.4.3.1. Total Incident Cases of CRC in Japan
    • 9.4.3.2. KRAS Incident Cases in CRC in Japan
    • 9.4.3.3. KRAS Variant Cases in CRC in Japan
• 9.5. KRAS Mutation in Pancreatic Cancer
  • 9.5.1. United States
    • 9.5.1.1. Total Incident Cases of Pancreatic Cancer in the United States
    • 9.5.1.2. KRAS Incident Cases in Pancreatic Cancer in the United States
    • 9.5.1.3. KRAS Variant Cases in Pancreatic Cancer in the United States
  • 9.5.2. EU4 and the UK
    • 9.5.2.1. Total Incident Cases of Pancreatic Cancer in EU4 and the UK
    • 9.5.2.2. KRAS Incident Cases in Pancreatic Cancer in EU4 and the UK
    • 9.5.2.3. KRAS Variant Cases in Pancreatic Cancer in EU4 and the UK
  • 9.5.3. Japan
    • 9.5.3.1. Total Incident Cases of Pancreatic Cancer in Japan
    • 9.5.3.2. KRAS Incident Cases in Pancreatic Cancer in Japan
    • 9.5.3.3. KRAS Variant Cases in Pancreatic Cancer in Japan
• 9.6. KRAS Mutation in LGSOC
  • 9.6.1. United States
    • 9.6.1.1. Total Incident Cases of LGSOC in the United States
    • 9.6.1.2. KRAS Incident Cases in LGSOC in the United States
    • 9.6.1.3. KRAS Variant Cases in LGSOC in the United States
  • 9.6.2. EU4 and the UK
    • 9.6.2.1. Total Incident Cases of LGSOC in EU4 and the UK
    • 9.6.2.2. KRAS Incident Cases in LGSOC in EU4 and the UK
    • 9.6.2.3. KRAS Variant Cases in LGSOC in EU4 and the UK
  • 9.6.3. Japan
    • 9.6.3.1. Total Incident Cases of LGSOC in Japan
    • 9.6.3.2. KRAS Incident Cases in LGSOC in Japan
    • 9.6.3.3. KRAS Variant Cases in LGSOC in Japan

10. Marketed Drugs

• 10.1. Key Competitors
• 10.2. LUMAKRAS/LUMYKRAS (sotorasib): Amgen
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Development
    • 10.2.4.1. Clinical Trial Information
  • 10.2.5. Safety and Efficacy
  • 10.2.6. Analyst Views
• 10.3. KRAZATI (adagrasib): Bristol Myers Squibb (Mirati Therapeutics)
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Clinical Development
    • 10.3.4.1. Clinical Trial Information
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Analyst Views
• 10.4. AVMAPKI + FAKZYNJA Co-Pack (avutometinib + defactinib): Verastem Oncology
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Clinical Development
    • 10.4.4.1. Clinical Trials Information
  • 10.4.5. Safety and Efficacy
  • 10.4.6. Analyst Views

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Safety and Efficacy Data of Phase I/II Emerging Drugs
• 11.3. Safety and Efficacy Data of Phase I Emerging Drugs
• 11.4. Divarasib (RG6330): Roche/Chugai/Genentech
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Development
    • 11.4.3.1. Clinical Trials Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Analyst Views
• 11.5. Daraxonrasib (RMC-6236): Revolution Medicines
  • 11.5.1. Product Description
  • 11.5.2. Other Developmental Activities
  • 11.5.3. Clinical Development
    • 11.5.3.1. Clinical Trials Information
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Analyst Views
• 11.6. Olomorasib (LY3537982): Eli Lilly and Company
  • 11.6.1. Product Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Development
    • 11.6.3.1. Clinical Trials Information
  • 11.6.4. Safety and Efficacy
  • 11.6.5. Analyst Views
• 11.7. MK-1084: Merck, Taiho, and Astex Pharmaceuticals
  • 11.7.1. Product Description
  • 11.7.2. Other Developmental Activities
  • 11.7.3. Clinical Development
    • 11.7.3.1. Clinical Trials Information
  • 11.7.4. Safety and Efficacy
  • 11.7.5. Analyst Views
• 11.8. Onvansertib: Cardiff Oncology
  • 11.8.1. Product Description
  • 11.8.2. Other Developmental Activities
  • 11.8.3. Clinical Development
    • 11.8.3.1. Clinical Trials Information
  • 11.8.4. Safety and Efficacy
  • 11.8.5. Analyst Views
• 11.9. DUPERT (fulzerasib/GFH925): Genfleet Therapeutics and Innovent
  • 11.9.1. Product Description
  • 11.9.2. Other Developmental Activities
  • 11.9.3. Clinical Development
    • 11.9.3.1. Clinical Trials Information
  • 11.9.4. Safety and Efficacy
  • 11.9.5. Analyst Views
• 11.1. ELI-002: Elicio Therapeutics
  • 11.10.1. Product Description
  • 11.10.2. Other Developmental Activities
  • 11.10.3. Clinical Development
    • 11.10.3.1. Clinical Trials Information
  • 11.10.4. Safety and Efficacy
  • 11.10.5. Analyst Views
• 11.11. D3S-001: D3 Bio
  • 11.11.1. Product Description
  • 11.11.2. Other Developmental Activities
  • 11.11.3. Clinical Development
    • 11.11.3.1. Clinical Trials Information
  • 11.11.4. Safety and Efficacy
  • 11.11.5. Analyst Views

12. KRAS Inhibitors: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebate
  • 12.4.2. Pricing Trends
  • 12.4.3 . Analogue Assessment
  • 12.4.4 . Launch Year and Therapy Uptake
• 12.5. Total Market Size of KRAS Inhibitors by Country in the 7MM
• 12.6. Total Market Size of KRAS Inhibitors by Indications in the 7MM
• 12.7. United States Market Size
  • 12.7.1. Total Market Size of KRAS Inhibitors in the United States
  • 12.7.2. Market Size of KRAS Inhibitors by Therapies in the United States
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of KRAS Inhibitors in EU4 and the UK
  • 12.8.2. Market Size of KRAS Inhibitors by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of KRAS Inhibitors in Japan
  • 12.9.2. Market Size of KRAS Inhibitors by Therapies in Japan

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW
• 16.4. Market Access and Reimbursement of KRAS Inhibitors

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight